Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emfizatamab - Sichuan Baili Pharmaceutical/SystImmune

Next Previous
Search
Drug Profile

Emfizatamab - Sichuan Baili Pharmaceutical/SystImmune

Alternative Names: GNC-038

Latest Information Update: 24 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 04 Mar 2025 Sichuan Baili Pharmaceutical plans a phase I trial for Rheumatoid arthritis in China (IV, Infusion) in March 2025 (NCT06857227)
  • 04 Mar 2025 Sichuan Baili Pharmaceutical plans a phase I trial for Systemic lupus erythematosus in China (IV, Infusion) in March 2025 (NCT06857214)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Leukaemia in China (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top